iBio, Inc. Common Stock Cash Flow Conversion Efficiency
iBio, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) has a cash flow conversion efficiency ratio of -0.073x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.23 Million) by net assets ($85.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of iBio, Inc. Common Stock (2007–2026)
Cash flow conversion efficiency of iBio, Inc. Common Stock from 2007 to 2026. This chart illustrates how iBio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest iBio, Inc. Common Stock stock price today for real-time trading data and today's change.
iBio, Inc. Common Stock Cash Flow Conversion Ratio Explained
iBio, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
iBio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iBio, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see iBio, Inc. Common Stock (IBIO) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dsr Wire
KO:069730
|
0.007x |
|
Lida Holdings Ltd
TW:4552
|
0.005x |
|
Stefstock
JSE:SSK
|
-2.100x |
|
BRAIN Biotech AG
XETRA:BNN
|
-2.326x |
|
Hwacheon Machi
KO:010660
|
-0.024x |
|
Sun Max Tech Ltd
TW:6591
|
0.021x |
|
Minupar Participações S.A
SA:MNPR3
|
0.111x |
|
Gemfields Group Limited
F:5PH
|
0.031x |
Annual Cash Flow Conversion Efficiency for iBio, Inc. Common Stock (2007–2026)
The table below shows the annual cash flow conversion efficiency of iBio, Inc. Common Stock from 2007 to 2026. Review financial agility of iBio, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $85.71 Million | $-23.22 Million | -0.271x | +73.66% |
| 2025-06-30 | $14.88 Million | $-15.30 Million | -1.028x | -18.20% |
| 2024-06-30 | $21.32 Million | $-18.55 Million | -0.870x | +56.03% |
| 2023-06-30 | $15.38 Million | $-30.44 Million | -1.979x | -232.32% |
| 2022-06-30 | $63.48 Million | $-37.80 Million | -0.595x | -115.03% |
| 2021-06-30 | $108.57 Million | $-30.06 Million | -0.277x | -17.46% |
| 2020-06-30 | $56.61 Million | $-13.35 Million | -0.236x | +95.86% |
| 2019-06-30 | $2.46 Million | $-13.97 Million | -5.688x | -582.03% |
| 2018-06-30 | $16.16 Million | $-13.48 Million | -0.834x | +43.52% |
| 2017-06-30 | $8.91 Million | $-13.16 Million | -1.477x | -339.80% |
| 2016-06-30 | $24.04 Million | $-8.07 Million | -0.336x | +20.20% |
| 2015-06-30 | $11.23 Million | $-4.72 Million | -0.421x | +37.66% |
| 2014-06-30 | $6.10 Million | $-4.12 Million | -0.675x | +29.47% |
| 2013-06-30 | $5.07 Million | $-4.85 Million | -0.957x | +1.78% |
| 2012-06-30 | $6.17 Million | $-6.01 Million | -0.974x | +96.41% |
| 2011-06-30 | $196.64K | $-5.34 Million | -27.147x | -1144.06% |
| 2010-06-30 | $1.08 Million | $-2.35 Million | -2.182x | -372.91% |
| 2009-06-30 | $4.39 Million | $-2.02 Million | -0.461x | -348.99% |
| 2008-06-30 | $-6.20 Million | $-1.15 Million | 0.185x | -5.46% |
| 2007-06-30 | $-4.33 Million | $-849.38K | 0.196x | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimiz… Read more